explore -WSS

explore

author：hotspot 2025-10-02 13:37:39 - browse：4864

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement comes just days after Eisai won final approval in the U.S. for its Alzheimer’s drug Leqembi.

Cheung will be replaced in his capacity as head of the Alzheimer’s unit by his brother-in-law Keisuke Naito, 34, who is currently chief ecosystem officer and chief strategy officer. He is also the son of Eisai CEO Haruo Naito.

Tatsuyuki Yasuno, current chief financial officer, will replace Cheung as head of Eisai’s U.S. unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： New documents shed light on MD Anderson Cancer Institute feud

WSS

CDC recommends rationing of RSV shot due to shortages

CDC recommends rationing of RSV shot due to shortages

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Cassava reveals details — and problems — with Alzheimer's study

Testing for cancer recurrence creates a new limbo for patients

hotspot

explore

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

Emergency medicine has repudiated 'excited delirium.' Now what?

The high cost of giving birth even with insurance

WHO may add ‘noma' to its list of neglected tropical diseases

Peter Hotez and the public health issue of online harassment

Alabama hospital puts IVF treatments on hold

FDA approval of Sarepta Duchenne genetic therapy gives me hope

6 phony surgeries that take placebo to the extreme

Walensky prepares to leave CDC — and Congress — behind

Alabama IVF ruling threatens families facing fatal genetic disease

focus

Traditional Chinese medicine benefits explored in new JAMA study

The pink breast cancer awareness ribbon needs a redesign

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

CDC recommends rationing of RSV shot due to shortages

Meta's Zuckerberg and Chan on track to put $50 billion into science

Physician subsidies by hospitals soar in wake of No Surprises Act

Wikipedia

explore

knowledge

entertainment